talaporfin (Laserphyrin) Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Talaporfin is a chlorin based photosensitizer used in photodynamic therapy (PDT).   Wikipedia

Chemistry

  • SMILES: CCc1c(C)c2cc3[nH]c(cc4nc([C@@H](CCC(=O)O)[C@@H]4C)c(CC(=O)N[C@@H](CC(=O)O)C(=O)O)c5[nH]c(cc1n2)c(C)c5C(=O)O)C(=C3C=C)C
  • InChIKey: VSEIDZLLWQQJGK-WSUYNKMOSA-N
  • Mol. Mass: 711.77
  • ALogP: 5.76
  • ChEMBL Molecules:
    talaporfin  
    talaporfin sodium  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

laserphyrin | l-aspartic acid, n-(3-(18-carboxy-20-(carboxymethyl)-8- ethenyl-13-ethyl-2,3-dihydro-3,7,12,17-tetramethyl-21h,23h- porphin-2-yl)-1-oxopropyl)-, (2s-trans)- | ls-11 | me2906 | monoaspartyl chlorin e6 | mono-l-aspartyl chlorin e6 | mr901 | n-aspartyl chlorin e6 | n-aspartylchlorin e6 | npe6 | talaporfin | talaporfin sodium | taporfin

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (20)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (20)


 

Astrocytoma (Phase 2)

Breast Neoplasms (Phase 1)

Carcinoma, Hepatocellular (Phase 3)

Choroidal Neovascularization (Phase 1)

Colorectal Neoplasms (Phase 3)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Head and Neck Neoplasms (Phase 1)

Liver Neoplasms (Phase 3)

Lower Urinary Tract Symptoms (Phase 2)

Macular Degeneration (Phase 1)

Mouth Neoplasms (Phase 1)

Neoplasm Metastasis (Phase 3)

Neoplasm Recurrence, Local (Phase 3)

Neurofibroma (Phase 1)

Pelvic Neoplasms (Phase 1)

Port-Wine Stain (Phase 1)

Prostatic Hyperplasia (Phase 2)

Rectal Neoplasms (Phase 1)

Sarcoma (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue